Wheat Bran
drugOn this page
Also known as Ae-wheat branCommon wheat branFood - plant sourceTriticum (wheat fibre)Triticum aestivum branTriticum aestivum seed huskTriticum hybernum branTriticum macha branTriticum sativum branTriticum sphaerococcum branTriticum vulgare (wheat) branWheat bran fibercrude
Summary
Wheat Bran (CHEMBL2108696) is a phase-3 clinical-stage unknown (ATC A06AC07); indicated across 1 condition including constipation disorder.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- ATC class: A06AC07
- Indications: 1 condition
- Clinical trials: 10
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108696 |
| Name | Wheat Bran |
| Type | Unknown |
| Max phase | 3 |
| ATC | A06AC07 |
Also known as: Ae-wheat bran, Common wheat bran, Food - plant source, wheat bran, Triticum (wheat fibre), Triticum aestivum bran, Triticum aestivum seed husk, Triticum hybernum bran, Triticum macha bran, Triticum sativum bran, Triticum sphaerococcum bran, Triticum vulgare (wheat) bran
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| constipation disorder | 3 | MONDO:0002203 | HP:0002019 |
Clinical trials
Total trials: 10.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 5 |
| PHASE1/PHASE2 | 2 |
| PHASE1 | 2 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00728403 | PHASE2 | UNKNOWN | Metabolic and Therapeutic Effects of American and Korean Red Ginseng in the Treatment of Type 2 Diabetes |
| NCT00981981 | PHASE2 | COMPLETED | Effect of the Molecular Weight of Oat β-glucan on Its Ability to Lower Serum Cholesterol |
| NCT01578837 | PHASE1/PHASE2 | COMPLETED | Combined Rg3-enriched Korean Red Ginseng and American Ginseng in the Management of Hypertension in Type 2 Diabetes |
| NCT02796989 | PHASE1/PHASE2 | COMPLETED | The Impact of Modified Wheat Bran on Carbohydrate Fermentation in the Colon in Healthy and Obese Subjects |
| NCT03741621 | PHASE2 | COMPLETED | Viscosity of Fibre Predicts Cholesterol-lowering in Healthy Individuals |
| NCT03741660 | PHASE2 | COMPLETED | Konjac-Mannan Improves Glycemia and Other Risk Factors for CHD in T2DM |
| NCT03741686 | PHASE2 | COMPLETED | Effect of Konjac-mannan in Individuals With Insulin-Resistance Syndrome |
| NCT01579656 | PHASE1 | COMPLETED | Effect of Flax, Poppy, Sesame & Salba on Postprandial Blood Glucose Response, Vascular, Appetite & Sensory Parameters |
| NCT01951443 | PHASE1 | COMPLETED | Korean Red Ginseng Rg3 Extract on Arterial Stiffness and Blood Pressure |
| NCT04590768 | Not specified | COMPLETED | Tolerance of Regular Meal Intake With Mycoprotein (TOMMY) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: constipation disorder